EOS Technology Investment Syndicate

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, established in 2012. The company focuses on modulating the innate immune system through the development of novel peptide therapeutics aimed at treating various conditions, including cancer, atopic dermatitis, psoriasis, and COVID-19. ILC Therapeutics is pioneering a new class of interferon medicines known as hybrid interferons, which combine features from different natural interferon subtypes into a single molecule. This innovative approach seeks to enhance efficacy and improve safety in therapeutic applications, ultimately enabling healthcare professionals to achieve better patient outcomes and advance treatments for serious diseases.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, specializing in the development, manufacturing, and distribution of wavelength tunable femtosecond lasers. Founded as a spin-out from Heriot-Watt University in 2013, it boasts a founding team with over 40 years of experience in ultrafast lasers. Chromacity's product lineup includes several advanced lasers such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, designed for life sciences and spectroscopy applications. The company also offers Spark-X and Spark-OPO models, which provide tunable femtosecond pulses across various wavelengths for applications in two-photon stimulation and spectroscopy, respectively. Their robust, patent-pending fiber-laser technology ensures reliable performance, complemented by a user-friendly web-based interface for easy operation. In addition to standard products, Chromacity collaborates with systems manufacturers to create custom OEM femtosecond and picosecond lasers tailored for specific engineering and materials processing needs. The company serves a global customer base across North America, the UK, and the Middle East.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, established in 2012. The company focuses on modulating the innate immune system through the development of novel peptide therapeutics aimed at treating various conditions, including cancer, atopic dermatitis, psoriasis, and COVID-19. ILC Therapeutics is pioneering a new class of interferon medicines known as hybrid interferons, which combine features from different natural interferon subtypes into a single molecule. This innovative approach seeks to enhance efficacy and improve safety in therapeutic applications, ultimately enabling healthcare professionals to achieve better patient outcomes and advance treatments for serious diseases.

Novosound Ltd, founded in 2016 and based in Edinburgh, United Kingdom, specializes in the design and manufacture of innovative ultrasound sensors that address the limitations of traditional technology. As the first spin-out from the University of the West of Scotland, Novosound employs groundbreaking thin-film manufacturing techniques to create highly customizable and scalable ultrasound solutions. The company’s products are utilized across various sectors, including aerospace, oil and gas, industrial applications, as well as in medical, veterinary, and dental fields. By developing advanced imaging sensors, systems, and software, Novosound enhances high-resolution ultrasound imaging, thereby providing clients with improved capabilities in non-destructive testing and diagnostics.

ENOUGH is a technology spin-out from the University of Strathclyde focused on developing and commercializing innovative patented technology for the production of mycoprotein, a meat alternative. The company integrates mycoprotein production within existing bio-refinery operations that also produce bio-ethanol and animal feed, promoting a sustainable circular economy. ENOUGH's mycoprotein-based products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions while employing a zero-waste fermentation process. This approach allows for the creation of food ingredients that contain all essential amino acids and are high in dietary fiber, providing consumers with a low-cost, sustainable protein option that serves as a meat substitute.

ENOUGH is a technology spin-out from the University of Strathclyde focused on developing and commercializing innovative patented technology for the production of mycoprotein, a meat alternative. The company integrates mycoprotein production within existing bio-refinery operations that also produce bio-ethanol and animal feed, promoting a sustainable circular economy. ENOUGH's mycoprotein-based products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions while employing a zero-waste fermentation process. This approach allows for the creation of food ingredients that contain all essential amino acids and are high in dietary fiber, providing consumers with a low-cost, sustainable protein option that serves as a meat substitute.

Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.

Provider of biotechnology genetics services intended to help clients focus on the global aquaculture supply chain. The company offers services like genotyping, pedigree reconstruction, gene expression, sex determination, triploidy validation, and more, enabling clients to meet the ever-expanding consumer demand for seafood.

Findie Development Limited, established in 2015 and based in London, United Kingdom, operates an online platform dedicated to discovering and streaming high-quality cinematic videos and short films from around the globe. The company curates a diverse collection of creative content, which is organized through a proprietary content engine that tailors recommendations to users based on their viewing preferences and interests. By bringing together a wide array of cinematic experiences in one accessible location, Findie aims to enhance the way audiences engage with film and video storytelling.

Digital Sports Arena (dba Gameday Live) is a BAFTA award winning team of game industry executives with a proven track record of delivering multi-million pound selling sports franchises. They have over a decade of experience in creating critically acclaimed and commercially successful sports management simulations. They set up Digital Sports Arena because they wanted to deliver a completely new gaming experience for fans of the genre. An experience which they think will change the landscape of sports simulation and head to head competition.